Bioceltix Statistics

Total Valuation

Bioceltix has a market cap or net worth of PLN 365.40 million. The enterprise value is 345.57 million.

Market Cap	365.40M
Enterprise Value	345.57M

Important Dates

The next estimated earnings date is Monday, November 25, 2024.

Earnings Date	Nov 25, 2024
Ex-Dividend Date	n/a

Share Statistics

Bioceltix has 4.92 million shares outstanding. The number of shares has increased by 16.64% in one year.

Current Share Class	n/a
Shares Outstanding	4.92M
Shares Change (YoY)	+16.64%
Shares Change (QoQ)	+0.64%
Owned by Insiders (%)	7.43%
Owned by Institutions (%)	18.46%
Float	3.83M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	8.14
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-21.98
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-24.96

Financial Position

The company has a current ratio of 7.21, with a Debt / Equity ratio of 0.00.

Current Ratio	7.21
Quick Ratio	3.26
Debt / Equity	0.00
Debt / EBITDA	n/a
Debt / FCF	-0.02
Interest Coverage	-273.92

Financial Efficiency

Return on equity (ROE) is -50.19% and return on invested capital (ROIC) is -31.71%.

Return on Equity (ROE)	-50.19%
Return on Assets (ROA)	-28.03%
Return on Capital (ROIC)	-31.71%
Revenue Per Employee	n/a
Profits Per Employee	-561,390
Employee Count	28
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +18.53% in the last 52 weeks. The beta is 1.66, so Bioceltix's price volatility has been higher than the market average.

Beta (5Y)	1.66
52-Week Price Change	+18.53%
50-Day Moving Average	73.47
200-Day Moving Average	73.35
Relative Strength Index (RSI)	46.69
Average Volume (20 Days)	3,586

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

Revenue	n/a
Gross Profit	-1.21M
Operating Income	-16.00M
Pretax Income	-15.74M
Net Income	-15.72M
EBITDA	-15.56M
EBIT	-16.00M
Earnings Per Share (EPS)	-3.80

Full Income Statement

Balance Sheet

The company has 20.04 million in cash and 210,029 in debt, giving a net cash position of 19.83 million or 4.03 per share.

Cash & Cash Equivalents	20.04M
Total Debt	210,029
Net Cash	19.83M
Net Cash Per Share	4.03
Equity (Book Value)	44.89M
Book Value Per Share	9.12
Working Capital	43.33M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -13.75 million and capital expenditures -99,062, giving a free cash flow of -13.85 million.

Operating Cash Flow	-13.75M
Capital Expenditures	-99,062
Free Cash Flow	-13.85M
FCF Per Share	-2.81

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Bioceltix does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-16.64%
Shareholder Yield	-16.64%
Earnings Yield	-5.12%
FCF Yield	-3.79%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a